PGX - TPMT StripAssayThe easy way to optimize thiopurine therapy using established innovations in diagnostics PGX-TPMT Assay. Key to efficient therapy. Thiopurines are widely used in the treatment of leukemias and autoimmune disorders, such as Crohn's disease and rheumatoid arthritis. Their use as immunosuppressants after organ transplantation is equally well established. Thiopurine-based drugs are metabolized by the enzyme thiopurine S-methyltransferase (TPMT). Impaired TPMT enzyme activity results in an accumulation of thiopurines and toxic effects on the bone marrow (myelosuppression). 6-Mercaptopurine and its pro-drug azathioprine are immunosuppressants acting via inhibition of DNA synthesis. Thiopurine compounds are converted to therapeutically inactive metabolites by the enzyme TPMT, which exists in different isoforms. TPMT alleles *2 and *3 encode variants with substantially reduced enzyme activity. Patients with low TPMT activity (poor metabolizers) accumulate higher concentrations of thiopurines when receiving standard dosage, and are therefore at elevated risk for side effects such as myelosuppression. The PGX-TPMT StripAssay® offers an easy way to identify the most frequent polymorphisms in the TPMT gene with therapeutic relevance.

The ViennaLab PGX-TPMT StripAssay® meets customer requirements Requirement ViennaLab’s offer Three simple steps. 6 h. Done. Probes for variants and controls combined on one teststrip. Automated or manual processing. Incubator.Thermocycler. Shaker. That is all you need. Software for interpretation of results is optional. The ViennaLab PGX-TPMT StripAssay® combines all these requirements. The ViennaLab PGX-TPMT StripAssay® • is based on reverse-hybridization of biotinylated PCR products • combines probes for variants and controls in a parallel array of allele-specific oligonucleotides • works with...